Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced Unresectable Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 06 May 2017
At a glance
- Drugs PLX 8394 (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Plexxikon
- 05 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 May 2018.
- 05 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Mar 2018.
- 05 May 2015 New trial record